Axiom Biosciences is considering an initial public offering in Hong Kong, a rare move for an American biotechnology firm, and one that would help it tap China’s booming clinical development capabilities.
Source: [Bloomberg Markets](https://www.bloomberg.com/news/articles/2026-07-21/us-based-axiom-seeks-hong-kong-ipo-to-tap-china-s-biotech-boom)